ocp192_en

ANNEXΡar /ΡageMoU2.10.2.1.1MoU2.10.2.1.1MoU2.10.2.1.1Action Deadline Comments StatusEuropean Social Fund, we plan to extend the program tomore beneficiaries while expanding the coverage ofhealthcare services.The government applies an automatic claw-backmechanism (every six months) to pharmaceuticalproducers which guarantees that the outpatientpharmaceutical expenditure (EOPYY budget) does notexceed the above targets.The government applies an automatic claw-backmechanism (every six months) to pharmaceuticalproducers which guarantees that the outpatientpharmaceutical expenditure (EOPYY budget) does notexceed the above targets.A note on the collection of claw back for 2013 for the firsthalf of 2013 is submitted.ContinuousContinuousSeptember2013MD for the claw-back was published (FEK 2045/22-8-2013). Letters about the amount of claw back weresent on 3/9/2013. The amounts were either offset orpaid.MD for 2014 claw-back target pending. Newdeadline: March 2014Progress report was submitted to EC/ECB/IMF on6/9/2013.Observed.Ongoing.NotObserved.Observed.MoU2.10.2.1.1A note on the collection of claw back for 2013 for the firsthalf of 2013 is submitted.December2013An updated progress report was submitted toEC/ECB/IMF on 3/2/2014.Observed.MoU2.10.2.1.2MoU2.10.2.1.3MoU2.10.2.2.1MoU2.10.2.2.1Activates contingency measures (including e.g. a crossthe-boardcut in prices or entry fee for the positive list), if,for any reason, the claw-back is not able to achieve thetarget. Such measures produce equivalent amount ofsavingsIn addition and if necessary, EOPYY introduces additionalincentives and mechanisms, including a prescription quotasystem for physicians, to ensure generic substitutionRevises downward the price of medicines, based on thethree EU countries with the lowest prices of price list inline with the provisions of Council Directive 89/105/EEC.Revises downward the price of medicines, based on thethree EU countries with the lowest prices of price list inline with the provisions of Council Directive 89/105/EEC.October 2013September2013Quarterly(Next lists tobe publishedby end June2013 andSeptember2013)QuarterlyThe pharmaceutical claw back process progressedsmoothly, so there is no need for contingencymeasures.The MD about incentives for insured citizens waspublished (FEK B 2219/9-9-2013). Measuresregarding incentives to pharmacies and doctors arein L. 4213 FEK A261/9-12-2013. Α MD regardingincentives for doctors was signed and published(113429/FEK Β3117/9-12-2013)The price list was published on 6/8/2013 (MD74725/6-8-2013). Corrective bulletin was publishedat 30/8/2013.The new price list was published at 12/2/2014 (MD14230/11-2-2014).Observed.Observed.Observed.Ongoing.Observed.MoU2.10.2.2.2MoU2.10.2.2.3MoU2.10.2.3.1MoU2.10.2.3.2On the basis of the report on the impact of the new profitmargins of pharmacies, reduce the profit margins down to15%.Ensures that EOPYY negotiates a 5% discount throughprice-volume or risk sharing agreements focusing on thetop spending medicines sold in EOPYY pharmacies.Update the positive list of reimbursed medicines and thelist of OTC medicines. These lists must be updated afterevery price bulletin or the corrective (deadlines shouldfollow 2.10.2.2.1 with some offset)Ensures full coverage of e-prescription to doctors,outpatient facilities and providers contracted by EOPYYand to all NHS facilities (health centres and hospitals).January 2014 New deadline was agreed (June 2014)Continuousfor 2013 and2014Quarterly(Next lists tobe publishedby end June2013 andSeptember2013)September2013Ongoing procedure. Relevant MD was published(FEK B2219/9-9-2013) that provides fornegotiations through price-volume or risk sharingagreements.The positive list was published (FEK 2467/2-10-2013 & 2477/3-10-2013). The list of OTC medicineswas published (FEK B 2840/7-11-2013).E-prescription coverage for medicines is 98% andfor the other medical acts (compulsory from April2013) is higher than 90%.NotObserved.Observed.Ongoing.Observed.Observed.MoU2.10.2.3.2MoU2.10.2.3.3MoU2.10.2.3.4E-prescribing is made compulsory and must include atleast 90 percent of all outpatient medical acts covered bypublic funds (medicines, referrals, diagnostics).Finalise the implementation of the system (API) wherebypharmacies electronically register any residual manualprescriptions from doctors into the e-prescriptionapplication established by IDIKA.Continue publishing prescription guidelines/protocols forphysicians, with priority for the most expensive and/ormostly used medicines, and makes them compulsoryContinuousSeptember2013ContinuousE-prescription coverage for medicines is 98% andfor the other medical acts (compulsory from April2013) is higher than 90%.Currently the coverage rate is 83% of prescriptions.Ongoing. Protocols are published on EOF websiteand continue to be developed.Observed.Observed.Observed.Ongoing.MoU2.10.2.3.5MoU2.10.2.3.6MoU2.10.2.3.7.iEnforce the application of prescription guidelines throughthe e-prescription system starting with at least 5therapeutic groupsFurther develop the e-prescription system by monitoringthe compulsory ICD-10 and enforcing SPC filters in the e-prescription system.(at a pace of 500 drugs per monthstarting October 2013).Enhance monitoring and assessment through:detailedmonthly auditing reports on the use of e-prescription inNHS facilities and by providers contracted by EOPYY.These reports are shared with the European Commission,ECB and IMF staff teams.September2013October 2013ContinuousOn 2 October, EOPYY announced the launch of theapplication of prescription guidelines through the e-prescription system for 5 therapeutic groups.The SPC filters are included in the e-prescriptionsystem by linking it with EOF database.December 2013 report was submitted in February.Observed.Ongoing.Observed.Observed.Ongoing.97